Pharma Firms Need To Pressure Politicians On Brexit Priorities

Pharmaceutical companies need to get their message over to MPs and MEPs about the risks of Brexit to medicines supply chains, and would do well to work more closely with patient groups to highlight the possible health risks of reduced access to medicines.

PS1806_Clouds Obscuring Sun_1055974544_1200.jpg — Brexit storm clouds continue to gather over the pharma sector

With the prospect of a “no-deal” outcome to the Brexit negotiations looking increasingly likely, pharmaceutical companies have been told that they need to do more to convince UK and EU policy makers of the need for market certainty and continued timely access to medicines after the UK leaves the EU.

According to a survey of UK members of parliament (MPs) and members of the European Parliament (MEPs) conducted by the consultancy Portland, 51% of MPs and 35% of MEPs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

UK And US Regulators In Sync On RWD External Control Arms

29 May 2025

• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

27 May 2025

• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.